Léčba pacienta s opakovaně progradující chronickou lymfocytární leukemií idelasibem a komplikace této léčby
| Title in English | Treatment of a patient with repeatedly progressing chronic lymphocytic leukemia with idelalisib and complications of this treatment |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Popularization text |
| MU Faculty or unit | |
| Citation | |
| Attached files | |
| Description | Chronic lymphocytic leukemia has a variable course of disease, determined by heterogenic genetic background, clinical and laboratory prognostic factors. Treatment of relapsed/refractory CLL remains a clinical challenge. New drugs, BCR signalling inhibitors, bring at least some hope to the patients. These drugs come with various side effects. Use of one of the new drugs, idelalisib, is connected with hepatotoxicity, colitis, pneumonitis, and opportune infections. When choosing the right drug for the patient, clinician must consider previous medical history, comorbidities and overall status of the patient. Though some of the complications cannot be avoided, the treatment with idelalisib brings benefit to the patient. |